A brain-penetrant triazolopyrimidine enhances microtubule-stability, reduces axonal dysfunction and decreases tau pathology in a mouse tauopathy model.

Abstract

BACKGROUND:

Alzheimer's disease (AD) and related tauopathies are neurodegenerative diseases that are characterized by the presence of insoluble inclusions of the protein tau within brain neurons and often glia. Tau is normally found associated with axonal microtubules (MTs) in the brain, and in tauopathies this MT binding is diminished due to tau hyperphosphorylation. As MTs play a critical role in the movement of cellular constituents within neurons via axonal transport, it is likely that the dissociation of tau from MTs alters MT structure and axonal transport, and there is evidence of this in tauopathy mouse models as well as in AD brain. We previously demonstrated that different natural products which stabilize MTs by interacting with β-tubulin at the taxane binding site provide significant benefit in transgenic mouse models of tauopathy. More recently, we have reported on a series of MT-stabilizing triazolopyrimidines (TPDs), which interact with β-tubulin at the vinblastine binding site, that exhibit favorable properties including brain penetration and oral bioavailability. Here, we have examined a prototype TPD example, CNDR-51657, in a secondary prevention study utilizing aged tau transgenic mice.

METHODS:

9-Month old female PS19 mice with a low amount of existing tau pathology received twice-weekly administration of vehicle, or 3 or 10 mg/kg of CNDR-51657, for 3 months. Mice were examined in the Barnes maze at the end of the dosing period, and brain tissue and optic nerves were examined immunohistochemically or biochemically for changes in MT density, axonal dystrophy, and tau pathology. Mice were also assessed for changes in organ weights and blood cell numbers.

RESULTS:

CNDR-51657 caused a significant amelioration of the MT deficit and axonal dystrophy observed in vehicle-treated aged PS19 mice. Moreover, PS19 mice receiving CNDR-51657 had significantly lower tau pathology, with a trend toward improved Barnes maze performance. Importantly, no adverse effects were observed in the compound-treated mice, including no change in white blood cell counts as is often observed in cancer patients receiving high doses of MT-stabilizing drugs.

CONCLUSIONS:

A brain-penetrant MT-stabilizing TPD can safely correct MT and axonal deficits in an established mouse model of tauopathy, resulting in reduced tau pathology.

• Authors: Bin Zhang, Yuemang Yao, Anne-Sophie Cornec, Killian Oukoloff, Michael J James, Pyry Koivula, John Q Trojanowski, Amos B Smith 3rd, Virginia M-Y Lee, Carlo Ballatore, Kurt R Brunden
• Journal: Molecular neurodegeneration (Mol Neurodegener) Vol. 13 Issue 1 Pg. 59 (11 07 2018) ISSN: 1750-1326 [Electronic] England
• PMID: 30404654 (Publication Type: Journal Article, Research Support, N.I.H., Extramural)

Chemical References

• Quinazolines
• Triazoles
• tau Proteins
• triazoloquinazoline

Topics

• Alzheimer Disease (drug therapy, metabolism)
• Animals
• Axonal Transport (drug effects)
• Axons (drug effects, metabolism)
• Brain (drug effects, metabolism)
• Disease Models, Animal
• Humans
• Mice
• Microtubules (drug effects, metabolism)
• Neurons (drug effects, metabolism)
• Quinazolines (pharmacology)
• Tauopathies (drug therapy, metabolism)
• Triazoles (pharmacology)
• tau Proteins (drug effects, metabolism)